🔎 Trials Near Me

Beranda › Mielofibrosis › New Jersey

Uji klinis Mielofibrosis di New Jersey

6 studi untuk Mielofibrosis mencari peserta di lokasi di New Jersey.

Kota di New Jersey

Teks studi resmi (Bahasa Inggris)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04176198

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  • Summit Medical Group Oncology, Berkeley Heights
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07357727

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • START New Jersey, East Brunswick
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05320198

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT06773195

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, New Brunswick
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • Hackensack University Medical Center, Hackensack
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT06479135

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.